© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
February 20, 2020
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
Unconventional Candidate For a Lung Cancer Hero
Perhaps a Pearl: An Experience That Led to Meeting Another Breast Cancer Survivor
An Oncology Nurse Wears Many Hats
Inaccurate Information on Cancer Diagnosis and Treatment Common on Social Media Sites